MORISHITA JINTAN CO.,LTD. Logo

MORISHITA JINTAN CO.,LTD.

Healthcare firm making supplements and pharma with patented seamless capsule technology.

4524 | T

Overview

Corporate Details

ISIN(s):
JP3924400009
LEI:
Country:
Japan
Address:
大阪市中央区玉造一丁目2番40号

Description

Morishita Jintan Co., Ltd. is a multifaceted healthcare company established in 1893, focused on promoting health and well-being. The company's operations encompass two primary areas: the manufacture and sale of its proprietary products, including the iconic "Jintan" brand of herbal pills, and the provision of Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services. It specializes in developing and producing dietary supplements, pharmaceuticals, quasi-drugs, cosmetics, and health foods. A key technological strength is its patented seamless capsule technology, which enables the creation of highly stable products like heat- and acid-resistant probiotics designed to remain viable until reaching the intestines. The company serves both direct consumers through mail-order and online channels, as well as business clients in the food, supplement, and pharmaceutical sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:34
確認書
Japanese 8.2 KB
2025-11-12 07:32
半期報告書-第89期(2025/04/01-2025/09/30)
Japanese 172.4 KB
2025-06-26 06:56
臨時報告書
Japanese 23.4 KB
2025-06-20 08:44
確認書
Japanese 8.1 KB
2025-06-20 08:41
内部統制報告書-第88期(2024/04/01-2025/03/31)
Japanese 23.1 KB
2025-06-20 08:35
有価証券報告書-第88期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-12 07:15
半期報告書-第88期(2024/04/01-2025/03/31)
Japanese 179.7 KB
2024-11-12 07:13
確認書
Japanese 8.1 KB
2024-06-27 04:45
臨時報告書
Japanese 24.9 KB
2024-06-26 06:23
確認書
Japanese 8.1 KB
2024-06-26 06:22
内部統制報告書-第87期(2023/04/01-2024/03/31)
Japanese 22.2 KB
2024-06-26 06:21
有価証券報告書-第87期(2023/04/01-2024/03/31)
Japanese 1.0 MB
2024-02-08 05:32
確認書
Japanese 8.1 KB
2024-02-08 05:31
四半期報告書-第87期第3四半期(2023/10/01-2023/12/31)
Japanese 162.1 KB
2023-11-09 05:31
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all MORISHITA JINTAN CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MORISHITA JINTAN CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MORISHITA JINTAN CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.